

## Protocol for the use of Parathyroid Hormone (PTH)

Two PTH preparations are available:

- teriparatide (Forsteo<sup>®</sup>) - a fragment of PTH
- recombinant human parathyroid hormone (Preotact<sup>®</sup>)

Treatment should be prescribed by doctors in the bone clinic, either from PRI or from Ninewells Hospital.

Treatment is distributed by a home delivery package – all registration forms to be sent to Ninewells Pharmacy fao Gordon Thomson.

Treatment should be considered only in postmenopausal women who are at extremely high risk of fracture, i.e. T-score less than –3.0, and who ALSO fulfil the following criteria:

- i) fragility fractures despite having been on a bisphosphonate for at least 12 months

OR

- ii) at least 2 vertebral fragility fractures with a T-score of less than –4.0 (i.e. extremely low BMD)

Patient must be willing to take daily subcutaneous injection and should NOT HAVE any of the following conditions:

- a) Hypercalcaemia
- b) Severe Renal failure
- c) Metabolic bone disease or raised alkaline phosphatase
- d) Previous skeletal radiotherapy

Dosage details:

Teriparatide: 20mcg sc once daily. Maximum duration of treatment 18 months  
PTH (Preotact<sup>®</sup>): 100mcg sc once daily for up to 24 months.

### Notes:

- a) Whilst taking PTH the patient should not be taking a bisphosphonate con-currently, but should be on calcium and Vitamin D unless there is a good reason to the contrary.
- b) Treatment should be given for a maximum of 18-24 months (see above), and followed by a bisphosphonate or some other antiresorptive agent